PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety, tolerability, pharmacokinetics (PK), and viral and clinical response to treatment with AVI’s proprietary NEUGENE® antisense compound, AVI-4065, in HCV patients. Preliminary results from this study were presented in May at the International Conference on Antiviral Research (ICAR).
